{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:03:19Z","timestamp":1785448999786,"version":"3.56.0"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Management of\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteraemia (SAB) requires prolonged intravenous (IV) antibiotic therapy delivered in hospital or through Hospital in the Home (HITH), often requiring peripherally inserted central catheters (PICCs) and substantial healthcare resources. Dalbavancin offers a consolidation strategy following blood\u2010culture clearance that may reduce health\u2010service utilisation. Australian data describing the economic implications of this approach remain limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aimed to estimate the potential health\u2010service cost impact of dalbavancin consolidation therapy for SAB within an Australian public healthcare setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective audit of adult patients with laboratory\u2010confirmed SAB managed through HITH within Canberra Health Services between June 2023 and July 2024. Patients were stratified according to duration of IV therapy delivered via HITH (\u226414\u2009days vs &gt;14\u2009days). Based on comparable efficacy demonstrated in the Dalbavancin as an Option for Treatment of\n                      <jats:italic>S. aureus<\/jats:italic>\n                      (DOTS)\u00a0randomised trial, a cost\u2010minimisation framework compared observed costs of standard IV therapy with projected costs under a dalbavancin consolidation model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty\u2010one patients were included (12 \u2264\u200914\u2009days; 29 &gt;\u200914\u2009days). Median HITH length of stay was 10 and 28\u2009days respectively. Median per\u2010patient total cost under standard IV therapy was AU$6313.98 (\u226414\u2009days) and AU$17\u2009668.00 (&gt;14\u2009days). Projected dalbavancin strategy costs were AU$5646.00 and AU$11\u2009827.00. Median per\u2010patient cost differences favoured dalbavancin by AU$667.98 in the \u226414\u2010day cohort and AU$5841.00 in the &gt;14\u2010day cohort. PICC placement occurred in 36 patients receiving standard therapy with five PICC\u2010related complications recorded; PICCs were not required under the projected dalbavancin strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within an Australian public healthcare setting, dalbavancin consolidation therapy for selected patients with SAB was projected to reduce per\u2010patient resource utilisation, particularly among those requiring prolonged HITH therapy. Reduced HITH bed utilisation and avoidance of central venous access were the principal contributors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.70572","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:40:38Z","timestamp":1785447638000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Projected health\u2010service cost impact of dalbavancin consolidation therapy for\n                    <i>Staphylococcus aureus<\/i>\n                    bacteraemia in an Australian public health system"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4075-528X","authenticated-orcid":false,"given":"Eli","family":"Dunn","sequence":"first","affiliation":[{"name":"Canberra Health Services The Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Canberra Health Services North Canberra Hospital  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Marr","sequence":"additional","affiliation":[{"name":"Canberra Health Services The Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Chiong","sequence":"additional","affiliation":[{"name":"Canberra Health Services The Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jinf.2019.09.018","article-title":"S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3\u2010antigen vaccine","volume":"79","author":"Marshall HS","year":"2019","journal-title":"J Infect"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong SY","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/j.1326-5377.2009.tb02841.x","article-title":"Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand","volume":"191","author":"Turnidge JD","year":"2009","journal-title":"Med J Aust"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"Hal SJ","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers TJ","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of Dalbavancin","volume":"61","author":"Molina KC","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once\u2010weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher HW","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","volume":"334","author":"Turner NA","year":"2025","journal-title":"JAMA"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.11652","article-title":"Pharmacokinetics of Dalbavancin in complicated Staphylococcus aureus bacteremia: a secondary analysis of the DOTS randomized clinical trial","volume":"9","author":"Lodise TP","year":"2026","journal-title":"JAMA Netw Open"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single\u2010dose versus weekly Dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne MW","year":"2016","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"e2511641","DOI":"10.1001\/jamanetworkopen.2025.11641","article-title":"Comparative effectiveness of long\u2010acting Lipoglycopeptides vs standard\u2010of\u2010care antibiotics in serious bacterial infections","volume":"8","author":"Goodman\u2010Meza D","year":"2025","journal-title":"JAMA Netw Open"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad044","article-title":"Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals","volume":"5","author":"Bai F","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"e_1_2_8_14_1","first-page":"1","article-title":"Clinical utility and cost effectiveness of long\u2010acting Lipoglycopeptides used in deep\u2010seated infections among patients with social and economic barriers to care","volume":"10","author":"Antosz K","year":"2021","journal-title":"Pharmacy (Basel)"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/13696998.2023.2190704","article-title":"Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS","volume":"26","author":"Valerio M","year":"2023","journal-title":"J Med Econ"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02385-22","article-title":"Evaluation of Dalbavancin use on clinical outcomes, cost\u2010savings, and adherence at a large safety net hospital","volume":"11","author":"Lueking R","year":"2023","journal-title":"Microbiol Spectr"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1473-3099(23)00756-9","article-title":"Efficacy and safety of an early oral switch in low\u2010risk Staphylococcus aureus bloodstream infection (SABATO): an international, open\u2010label, parallel\u2010group, randomised, controlled, non\u2010inferiority trial","volume":"24","author":"Kaasch AJ","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02345-19","article-title":"Efficacy of early Oral switch with \u03b2\u2010lactams for low\u2010risk Staphylococcus aureus bacteremia","volume":"64","author":"Bupha\u2010Intr O","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2025.13717","article-title":"New pathways to treat Staphylococcus aureus bacteremia: connecting the DOTS","volume":"334","author":"EK MC","year":"2025","journal-title":"JAMA"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf471","article-title":"Long\u2010acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?","volume":"81","author":"MacPhail A","year":"2026","journal-title":"J Antimicrob Chemother"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:40:41Z","timestamp":1785447641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":19,"alternative-id":["10.1111\/imj.70572"],"URL":"https:\/\/doi.org\/10.1111\/imj.70572","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2026-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"imj.70572"}}